Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial

Peer Review reports

Original Submission
2 Jul 2013	Submitted	Original manuscript
13 May 2014	Reviewed	Reviewer Report - Giuliana Cortese
13 Jun 2014	Author responded	Author comments - George Fountzilas
Resubmission - Version 2
13 Jun 2014	Submitted	Manuscript version 2
21 May 2013	Reviewed	Reviewer Report - Sara Hurvitz
6 Jun 2013	Reviewed	Reviewer Report - ahmad awada
13 Jun 2014	Author responded	Author comments - George Fountzilas
Resubmission - Version 3
13 Jun 2014	Submitted	Manuscript version 3
21 Jun 2014	Reviewed	Reviewer Report - Sara Hurvitz
2 Jul 2014	Reviewed	Reviewer Report - Giuliana Cortese
Resubmission - Version 4
	Submitted	Manuscript version 4
Publishing
4 Jul 2014	Editorially accepted
15 Jul 2014	Article published	10.1186/1471-2407-14-515

Back to article page